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Predicting the Acute Liver Toxicity of Aflatoxin B1 in Rats
and Humans by an In Vitro–In Silico Testing Strategy
Ixchel Gilbert-Sandoval,* Sebastiaan Wesseling, and Ivonne M. C. M. Rietjens
Scope: High-level exposure to aflatoxin B1 (AFB1) is known to cause acute
liver damage and fatality in animals and humans. The intakes actually causing
this acute toxicity have so far been estimated based on AFB1 levels in
contaminated foods or biomarkers in serum. The aim of the present study is
to predict the doses causing acute liver toxicity of AFB1 in rats and humans by
an in vitro–in silico testing strategy.
Methods and results: Physiologically based kinetic (PBK) models for AFB1 in
rats and humans are developed. The models are used to translate in vitro
concentration–response curves for cytotoxicity in primary rat and human
hepatocytes to in vivo dose–response curves using reverse dosimetry. From
these data, the dose levels at which toxicity would be expected are obtained
and compared to toxic dose levels from available rat and human case studies
on AFB1 toxicity. The results show that the in vitro–in silico testing strategy
can predict dose levels causing acute toxicity of AFB1 in rats and human.
Conclusions: Quantitative in vitro in vivo extrapolation (QIVIVE) using PBK
modeling-based reverse dosimetry can predict AFB1 doses that cause acute
liver toxicity in rats and human.
1. Introduction
Aflatoxin B1 (AFB1) is a mycotoxin with well-established chronic
effects, including increased risk of liver cancer development in
humans.[1] The effects induced by acute exposure to relatively
higher dose levels of AFB1 have been explored less extensively.[2]
In humans, acute exposure to AFB1 has been identified from
described aflatoxicosis outbreaks, in which clinical symptoms
could be associated with the consumption of AFB1 contaminated
food.[3,4] More recently, biomarkers were used to confirm AFB1
exposure in individuals, for instance during the aflatoxicosis out-
break in Kenya in 2004 where 317 cases and 125 deaths were re-
ported, or in the outbreak in Tanzania in 2016 with 68 cases and
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a 30% fatality rate.[5–7] Aflatoxicosis
refers to the toxic liver injury caused by
aflatoxin, featuring jaundice, hepatitis,
vomiting, and abdominal pain.[3,5,6] De-
pending on the exposure and duration,
two types of aflatoxicosis are observed,
the first resulting in acute liver failure
and subsequent illness or death, and the
second being a sublethal intoxication
with nutritional and immunological
consequences.[8,9] From previously re-
ported outbreaks, mortality rates in
humans with acute aflatoxicosis are
estimated to be between 27% and 60%,
with children being more sensitive than
adults.[4,7–9]
Based on the estimated intake of AFB1
and the onset of symptoms reported in
three aflatoxicosis outbreaks, doses of
AFB1 that could result in acute aflatoxi-
cosis and present a risk of fatality in hu-
mans have been estimated to be around
20–100 µg kg−1 bw per day for a period of
1–3 weeks.[4] Joint FAO/WHO Expert Committee on Food Addi-
tives (JECFA)[9] reported a similar dose range, 20–120 µg kg−1
bw per day, derived from the AFB1 adduct concentrations per
mg serum albumin detected in samples collected from victims
of the 2004 outbreak in Kenya.[2,10] However, exposure assess-
ments based on the AFB1 occurrence levels in food and/or the
albumin-adduct biomarker have uncertainty. The former may be
affected by the variability in a food product with heterogeneous
contamination, and the latter may rather be related to chronic
instead of acute AFB1 exposure since for recent exposures the
measurement of aflatoxin M1 or aflatoxin-N7-guanine adducts is
considered a better indicator.[11]
In addition to human case studies, adverse effects upon acute
AFB1 exposure have also been characterized in different animal
models showing different sensitivities depending on the animal
species, strain, sex, and age of the animals.[12] Given that the
acute dose levels resulting in human liver toxicity have mainly
been derived from human case studies estimating the corre-
sponding dose levels based on levels in the contaminated food, it
is of interest to investigate whether dose levels for acute toxicity
can also be derived by using physiologically based kinetic (PBK)
modeling-based reverse dosimetry.[13] Within this context it is rel-
evant to note that data on in vivo kinetics of AFB1 are available
for rats and even for humans exposed to low dose levels,[14,15] al-
though these data have, to the best of our knowledge, not yet been
used to facilitate quantitative in vitro in vivo extrapolation (QI-
VIVE) predicting dose–response behavior for acute liver toxicity
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of AFB1. The use of PBK modeling-based reverse dosimetry to
perform QIVIVE has previously been shown to provide adequate
predictions for in vivo acute liver toxicity of the pyrrolizidine al-
kaloids lasiocarpine and riddelliine, or for in vivo kidney toxicity
of aristolochic acid.[16–18]
The aim of the present study was to use the PBK modeling-
based reverse dosimetry approach to perform QIVIVE to predict
dose response data for acute liver toxicity of AFB1 in rats and
humans. To this end, a PBK model for AFB1 was developed for
both rats and humans. Using these PBK models concentration–
response curves describing in vitro toxicity of AFB1 in rat and
human primary hepatocytes, were translated into in vivo dose–
response curves for acute liver toxicity by reverse dosimetry. Pre-
dictions made were evaluated against available in vivo toxicity
data.
2. Experimental Section
2.1. Chemicals
AFB1 and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) were purchased from Sigma-Aldrich
(Zwijndrecht, The Netherlands). Cryopreserved pooled rat he-
patocytes (Sprague Dawley), pooled human hepatocytes (pooled
from 5-donors, 2x lot HPP1834236 and 1x lot HPP1825348),
cell maintenance supplement pack, fetal bovine serum (FBS),
and Williams E Medium (WEM, A1217601) were purchased
from ThermoFisher (Naarden, The Netherlands). Trypsin-EDTA
was purchased from Gibco (Paisley, Scotland, UK). DMSO was
obtained from Acros Organics (Geel, Belgium).
2.2. General Outline for PBK Modeling-Based Reverse Dosimetry
The PBK model-based reverse dosimetry steps consist of 1) es-
tablishing in vitro concentration–response curves for the toxicity,
2) defining a PBKmodel describing in vivo kinetics using kinetic
parameters defined in vitro, 3) evaluation of the PBK model pre-
dictions against available in vivo data on kinetics, 4) translation of
the in vitro concentration–response curves for toxicity into in vivo
dose–response curves for toxicity using the PBKmodels, 5) deriv-
ing a point of departure (POD) from the in vivo dose–response
curves obtained and 6) comparison of the POD to available in vivo
data.[16,18]
2.3. In Vitro Cytotoxicity Concentration–Response Curves
Primary rat and human hepatocytes, and HepaRG cells
(Biopredic International) were used to define the in vitro
concentration–response curves for cytotoxicity. To this end, the
hepatocytes were seeded at a density of 5 × 104 cells per well
(5 × 105 cells mL−1) into 96-well plates according to the supplier’s
protocol and cultured in plating medium for 6 h. Undifferen-
tiated HepaRG cells were seeded at a density of 9 × 103 cells
per well (9 × 104 cells mL−1) and were differentiated according
to the supplier’s protocol. Following the preincubation, medium
was replaced by serum free medium containing different con-
centrations of AFB1 ranging from 0 to 50 µm for hepatocytes,
and for HepaRG cells from 0 to 100 µm, added from 200 times
concentrated stock solutions in DMSO (final DMSO concentra-
tion 0.5% v/v).Mitochondrial activitymeasured by theMTT assay
was used as a viability endpoint. After 24 h treatment, 10 µLMTT
inmedium (5mgmL−1) were added (final concentration 0.45 mg
mL−1) and cells were incubated for an additional 3 h. Cells were
lysed and the formazan crystals formed were dissolved by addi-
tion of 100 µL DMSO. The absorbance of the formazan solution
was measured at 562 nm, and the absorbance values were cor-
rected for the background absorbancemeasured at 620 nm using
a microplate reader spectrophotometer (SpectraMax M2, USA).
Relative cell viability (%) was calculated as (mean absorbance of
sample/mean absorbance of vehicle control) × 100%. Each con-
centration was tested in at least three replicates, and three inde-
pendent experiments were carried out.
2.4. Fraction Unbound (fub) in Plasma and Plasma to Blood
Conversion
For the reverse dosimetry, the unbound concentrations in vitro
are set equal to the unbound concentrations in vivo, since the tox-
icity is ascribed to unbound AFB1. AFB1 can bind non-covalently
to serum albumin reducing the amount of free AFB1 in vitro and
in vivo.[19–21] Thus, to perform reverse dosimetry, the in vitro con-
centrations were first corrected for the difference in protein bind-
ing in the in vitro and in vivo situation using Equation (1):
CAFB1, blood =
CAFB1, in vitro × fub, in vitro
fub, blood
(1)
where CAFB1, blood is the total concentration of AFB1 in blood,
CAFB1, in vitro the total AFB1 concentration in vitro, and fub the frac-
tion unbound in vitro or in blood. The exposure medium used in
vitro was serum free, so the fub, in vitro was considered to equal 1.0.
The fub, blood was assumed to be equal to the fub for AFB1 in human
plasma amounting to 0.16. This value was derived in silico using
the fu,p Predictor software.[22] For rats, the fub, blood was considered
the same as for humans. Since the PBKmodels predict the AFB1
concentration in blood, for evaluation of the model performance,
the plasma concentrations of AFB1 from in vivo kinetic studies
were converted to blood concentrations to enable comparison to
the model predictions, assuming that blood concentrations are
0.6 and 0.55 times the plasma concentrations in rats and humans,
respectively.[23–25]
2.5. PBK Model for Rats and Humans
The conceptual PBK model used in the present study to de-
scribe AFB1 kinetics in rats and humans is shown in Figure 1.
The model follows previous models which include a separate
compartment for liver as the metabolizing compartment, and
compartments for stomach, intestine, fat, kidney, rapidly per-
fused tissue, slowly perfused tissue and blood.[26,27] In order to
describe the transition from stomach to the small intestine and
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Figure 1. Schematic representation of the PBK model for AFB1 in rats and humans.
Table 1. Kinetic parameters used for the PBK model for rats and humans.
Liver tissue AFB1 total Conversion AFQ1 formation AFBO formation Reference
Vmax
a)
Km
b)
Vmax
a)
S50
c)
n
d)
Vmax
a)
S50
c)
n
d)
Rat S9 fraction 0.0027 13 — — — — — — [35]
Human microsomes — — 0.003469 427 1.2 0.000542 197 1.1 [36]
a)Vmax in µmol mg
−1 S9 fraction or microsomal protein min−1; b)Michaelis–Menten constant in µm; c)Analogous to Km but used in the Hill equation for sigmoidal kinetics in
µm (Equation (3)); d)n, Hill coefficient.
the transition within the small intestine the model contains a
stomach compartment emptying into the small intestine com-
partment divided in 7 subcompartments.[26,27] AFB1 is absorbed
by the small intestine following first order kinetics, after which it
is transported to the liver via the hepatic portal vein.[28–32] The ab-
sorption rate constant in the small intestine (ka) for the rat PBK
model was set at 5.84 h−1,[28] while for the human PBK model a
ka of 5.05 h−1 was used.[15] The ka of 5.84 h−1 and of 5.05 h−1 was
assumed to be the same for the 7 intestinal subcompartments
in rats and humans, respectively. Physiological parameter values
for the model, such as tissue volumes and blood flows, were
obtained from literature.[33] Physicochemical parameters such
as tissue/blood partition coefficients applied in the models were
calculated based on the method reported by DeJongh et al.[34]
using the logarithmic partition ratio of AFB1 for n-octanol/water
(log(KD)AFB1) of 1.15667 obtained using the software Chem3D
(version 18, PerkinElmer, MA, USA). Both physiological and
physiochemical parameters are presented in Table S1, Support-
ing Information. The PBK model equations were coded and
numerically integrated into Berkeley Madonna (version 8.3.18,
UC Berkeley, CA, USA) using Rosenbrock’s algorithms for
solving stiff differential equations. The model code describing
the PBK models can be found in Supporting Information.
2.6. Kinetic Parameters
The kinetic parameters describing the clearance of AFB1 in rats
and humans were obtained from literature (Table 1). In rats, the
kinetic parameters,Vmax andKm, describing the hepatic clearance
of AFB1were obtained from incubations with rat liver S9 fraction
from 28-day old F344 rats.[35] In humans, the kinetic parameters
for AFB1were obtained from themetabolite formation in incuba-
tions with microsomes from 13 human livers, reporting the for-
mation of aflatoxin Q1 (AFQ1) and AFB1 8,9-epoxide (AFBO).[36]
Given that AFQ1 is the major product of AFB1 metabolism in
humans,[37] the geometricmean of the kinetic constants from the
13 human liver microsomes for the formation of AFQ1 and the
geometric mean of the kinetic constants from the 13 human liver
microsomes for the formation of AFBOwere used to describe the
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clearance of AFB1 in humans. The kinetics in the rat model were
set to follow Michalis–Menten kinetics (Equation (2)) while, and,
in line with what was reported before, in humans the kinetics
were set to follow sigmoidal kinetics (Hill Equation)[36,38–42] as
seen in Equation (3):
v = Vmax × S
Km + S
(2)
v = Vmax × S
n
Sn50 + Sn
(3)
where Vmax is the maximum velocity, Km is the Michaelis con-
stant, S is the substrate concentration, S50 is analogous to Km, the
substrate concentration at half Vmax, and n is the Hill coefficient.
The in vitro kinetic parameter Vmax was scaled from microsomal
preparations to a whole liver considering an estimated S9 fraction
protein yield of 125 mg S9 fraction protein g−1 liver for rat[43] and
a microsomal protein yield of 39.46 mg microsomal protein g−1
liver for human.[44] The Km and S50 parameters were assumed to
be equal in vitro and in vivo.
2.7. Sensitivity Analysis and PBK Model Evaluation
To identify the parameters that affect the predicted maximal liver
blood concentrations (CVLmax) to the largest extent, sensitivity co-
efficients (SC)[45] were determined as follows:
SC =
(C′ − C)
(P′ − P)
× P
C
(4)
where P is the initial PBK model parameter, C the initial output
of the model calculation, and P′ is the modified parameter con-
sidering a 5% increase, and C′ the modified output obtained by
the model upon the 5% increment in parameter P. The sensitiv-
ity analysis was conducted at oral dose levels of 0.4 µg kg−1 bw
and 5 mg kg−1 bw for the rat model, and of 3.74 × 104 µg kg−1
bw per day and 120 µg kg−1 bw per day for humans, representing
in rats an intake level used in studies with repeated relatively low
dose levels and an acute high dose intake, and in humans a low
and a high dietary intake of AFB1.[9,11,15,46] Each parameter was
analyzed individually, keeping the other parameters to their ini-
tial values. Only parameters with an SC above an absolute value
of 0.1 are presented.
To evaluate the performance of the PBK model, AFB1 con-
centrations in human or rat plasma reported in in vivo studies
available in the literature[15,47] were transformed to concentra-
tions in whole blood assuming that blood concentrations are 0.6
and 0.55 times the plasma concentrations in rats and humans.
This enabled comparison to the PBK model predictions for
blood concentrations (CB). In rats, in vivo kinetic data for AFB1
levels in plasma after oral exposure were reported in two studies
(Table S2, Supporting Information). Although in one of the
studies, AFB1 was co-administered with 0.5 mg kg−1 bw T-2,[47]
the data on AFB1 quantified in plasma by LC-MS were used for
comparison assuming T-2 would not affect AFB1 bioavailability.
The study by Coulombe Jr and Sharma,[14] used radiolabelled
AFB1 and quantified the radioactivity, reporting the level of both
AFB1 and its metabolites in plasma samples. Both studies used
Sprague Dawley rats, and exposed them orally to 0.5 mg kg−1 bw
and 0.6 mg kg−1 bw, respectively. In vivo kinetic data for AFB1
available for the evaluation of the human PBKmodel, were taken
from the study of Jubert et al.[15] reporting levels of AFB1 equiv-
alents in plasma of 4 human volunteers who were exposed to an
oral low-dose (30 ng) of 14C labelled AFB1 (3.74 × 10−7 mg kg−1
bw). For this comparison of the PBK model-based predictions
the body weight in the human PBK model was set at 82.4 kg, the
average body weight of the 4 volunteers. (Table S3, Supporting
Information).
2.8. Translation of the In Vitro Concentration–Response Curves
to In Vivo Dose–Response Curves by Reverse Dosimetry
The PBK modeling-based reverse dosimetry approach was ap-
plied for translating the in vitro concentration–response curves
to in vivo dose–response curves. In vitro concentrations were cor-
rected for differences in protein binding in the in vitro and in
vivo situation (Equation (1)). The CAFB1, blood thus obtained was
assumed to equal the maximum concentration of AFB1 in liver
blood (CLVmax) in the PBK models. To obtain the corresponding
oral dose levels of AFB1 in the process denoted as reverse dosime-
try, a parameter plot of the maximum concentration of AFB1 in
blood liver (CVLmax) against the oral dose (mg kg
−1 bw) was used.
2.9. Analysis of In Vitro Concentration–Response Data and of
Predicted In Vivo Dose–Response Data
From the in vitro concentration–response curves the EC50 values
for in vitro toxicity were obtained using the dose–response stimu-
lation non-linear regression model by GraphPad Prism, 5.0 soft-
ware (San Diego, CA). For the predicted in vivo dose–response
curves, the lower and upper bounds of the benchmark dose re-
sulting in a 10% extra response above background (BMDL10-
BMDU10) were determined using the model averaging of the fit-
ted dose–response models using the PROAST software (version
38.9, The Dutch National Institute for Public Health and the En-
vironment, The Netherlands).
2.10. Evaluation of the Combined In Vitro PBK Approach
To evaluate the outcome from the PBK model-based reverse
dosimetry approach, the predicted BMDL10-BMDU10 ranges for
in vivo liver toxicity in rats were compared with PODs derived
from in vivo acute liver toxicity data from literature[48,49] and
with reported estimated median lethal doses (LD50) of AFB1 for
rats[50–53] (both detailed in Tables S4 and S5, Supporting Informa-
tion). Comparison to the LD50 assumes that the acute liver toxic-
ity would be the cause of the fatal outcome and the results of the
comparison should be considered keeping this in mind. For hu-
mans, the PBK model-based reverse dosimetry predictions were
evaluated with the suspected doses that cause acute aflatoxico-
sis and possibly death of 20–100 µg kg−1 bw per day estimated by
Wild and Gong (2009) and of 20–120 µg kg−1 bw per day reported
by JECFA (2018).
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Figure 2. Concentration response curves for the cytotoxicity of AFB1 (µm) in A) rat and B) human cell models upon 24 h exposure in medium without
serum (mean values+ SD) asmeasured in the present study and reported in literature. Circle symbols with dotted curves correspond to fresh hepatocytes.
Triangle symbols to cryopreserved hepatocytes, and diamonds to HepaRG cells. CP: cryopreserved.
3. Results
3.1. In Vitro Cytotoxicity
The concentration–response curves for the in vitro cytotoxicity
of AFB1 assessed by the MTT assay performed with serum-free
medium using cryopreserved rat hepatocytes, cryopreserved hu-
man hepatocytes and HepaRG cells are shown in Figure 2. Fig-
ure 2 also includes concentration–response curves from litera-
ture obtained using serum-free medium.
Figure 2A shows that the in vitro concentration–response
curves obtained in the present study for rat cryopreserved he-
patocytes, result in EC50 values that are about 100-fold higher
than those reported for fresh hepatocytes.[54,55]
Figure 2B shows that concentration–response curves obtained
in the present study for cryopreserved human hepatocytes and
HepaRG cells are comparable. Figure 2B, also presents data re-
ported in the literature for cytotoxicity of AFB1 in human liver
models as reported in other studies. The EC50 values derived from
the curves reveal that for the human hepatocytes the cryopre-
served hepatocytes result in cytotoxicity curves with EC50 values
that are about 5–13-fold higher than those obtained with fresh
hepatocytes, indicating the fresh hepatocytes to be more sensi-
tive, with the difference being less than what was observed for the
rat hepatocytes. Comparison of data from studies using HepaRG
cells exposed to AFB1 reveals some variability between studies
as the EC50 obtained in the different studies varies up to 4.7-fold
with especially the value reported by Rushing and Selim[56] meas-
ured by flow cytometry instead of the MTT assay, being lower.
The EC50 of all the curves are presented in Table S6, Supporting
Information.
3.2. PBK Model Description, Prediction, and Evaluation
Figure 3 shows the PBKmodel-based predictions for the time de-
pendent AFB1 concentrations in blood of rat (Figure 3A) and hu-
man (Figure 3B). In rats, the predicted Cmax (10.08 ng mL
−1) was
only 1.01-fold higher than theCmax in blood upon exposure of rats
to 0.5 mg kg−1 bw.[47] Also, the predicted Tmax, the time to reach
the Cmax, of 20 min, is close to the value reported by Han et al.
[47]
of 10.2 min (0.17 h). For the human model, the Cmax for the 4
human volunteers reported by Jubert et al.[15] was about 1.2–2.1-
fold higher than theCmax predicted (0.39 pgmL
−1). The predicted
Tmax (≈35 min) is 1.7-fold lower than what was observed for the 4
human individuals, but since for the reverse dosimetry only Cmax
values are used, this deviation will not affect the subsequent use
of the model for reverse dosimetry.
3.3. Sensitivity Analysis
Figure 4 shows the results of the sensitivity analysis presenting
the parameters that affect the PBK model prediction for Cmax to
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Figure 3. PBK model-predicted time-dependent blood concentration of AFB1 in A) rats and B) humans upon an oral dose of 0.5 mg kg−1 bw oral (red
line) and 0.374 ng kg−1 bw (blue line) respectively. Reported time-dependent blood concentrations depicted as symbols, were calculated from reported
plasma concentrations assuming that blood concentrations are 0.6 and 0.55 times the plasma concentrations in rats and humans, respectively.[23–25]
the highest extent. In both the rat and human models, the vol-
ume of the liver (VLc), the stomach emptying rate (ksto), the ab-
sorption constant rate (ka), the scaling factors to whole liver (in
rats the mg S9 fraction protein per g liver tissue [S9PL] and in
humans the mg microsomal protein per g liver tissue [MPL]), as
well as the kinetic parameters for AFB1 conversion or metabo-
lite formation, influence the model. Additionally, in humans, the
body weight (BW), the blood flow to the liver (QLc), the blood
flow to the rapidly perfused tissues (QRc), the blood flow to the
slowly perfused tissues (QSc), as well as the Hill coefficient used
to describe the formation of AFQ1 (nAFQ1) and the formation of
AFBO (nAFBO) also appeared to be influential parameters.
3.4. Translation of the In Vitro Concentration Response Curves to
In Vivo Dose–Response Curves
Figure 5 shows the predicted in vivo dose–response curves
for acute liver toxicity of AFB1 in rats and humans. The
dose–response curves were obtained using PBK model-based
facilitated reverse dosimetry converting all in vitro concentration
response curves depicted in Figure 2 (Table S7, Supporting
Information).
3.5. Evaluation of the Predicted In Vivo Liver Toxicity
Due to the differences between cryopreserved and fresh hepato-
cytes in both rats and humans, reflected by the different EC50
values (Figure 2; Table S6, Supporting Information), the PODs
used for the evaluation were derived from the dose–response
curves predicted based on the data obtained with fresh hepato-
cytes and not from the data obtained with cryopreserved hepa-
tocytes or HepaRG cells since these can be expected to result in
an underprediction of the in vivo AFB1 toxicity (Table S8, Sup-
porting Information). Figure 6, presents a visual comparison of
the predicted BMDL10-BMDU10 values for acute AFB1 toxicity
in rats compared with the POD values obtained from data on liver
toxicity markers after a single acute exposure to AFB1[48,57] and
after a repeated exposure (daily over 7 days).[49] Taken together,
the predicted BMDL10-BMDU10 values from the fresh F344 and
Sprague Dawley rat hepatocytes match the POD values derived
from the single and repeated exposure data on AFB1 induced
acute liver toxicity quite well. Figure 6 also presents the LD50 val-
ues for lethality upon a single oral dose of AFB1. These LD50 val-
ues are generally somewhat higher than the observed and pre-
dicted POD values for acute liver toxicity, which may be in line
with the fact that the lethality endpoint likely requires higher dose
levels than liver damage as such.
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Figure 4. Normalized sensitivity coefficients for the parameters of A) rat and B) human PBK model for AFB1. The sensitivity analysis for the rat model
(A) was performed at single oral doses of 0.4 µg kg−1 bw (gray bars) and 5 mg kg−1 bw (white bars). The sensitivity analysis for the human model (B)
was performed at single oral doses of 3.74 × 10−4 µg kg−1 bw (gray bars) and 120 µg kg−1 bw (white bars). VLc = volume of the liver, ksto = stomach
emptying rate, ka = absorption rate constant, S9PL = scaling factor from liver S9 fraction to whole liver, VmaxAFB1c = Vmax of AFB1 conversion,
KmAFB1c = Km of AFB1 conversion, BW = body weight, QLc = blood flow to liver, QRc = blood flow to rapidly perfused tissues, QSc = blood flow to
slowly perfused tissues, MPL = scaling factor from liver microsomes to whole liver, Vmax AFQ1 = Vmax of AFQ1 formation, S50AFQ1 = S50 of AFQ1
formation, Vmax AFBO = Vmax of AFBO formation, S50AFBO = S50 of AFBO formation, nAFQ1 = Hill coefficient for AFQ1 formation, nAFBO = Hill
coefficient for AFBO formation.
Figure 7, shows the comparison of the predicted BMDL10-
BMDU10 values for acute liver toxicity in humans derived from
data obtained in fresh human hepatocytes.[54] The predicted
BMDL10-BMDU10 values amount to 77–519 µg kg−1 bw with
the BMDL10 of 76 µg kg−1 bw being in line with the values of
20–120 µg kg−1 bw per day and of 20–100 µg kg−1 bw per day re-
ported in the literature for the onset of acute toxicity of AFB1 in
humans.[4,9]
4. Discussion
In humans, acute liver toxicity caused by AFB1 has been re-
ported but specific aflatoxin exposure doses casing toxicity
are unknown due to the difficulty to relate disease outcomes
with a specific oral AFB1 consumption.[11,58] In this study we
aimed to use an in vitro PBK model-based reverse dosimetry
approach to predict oral dose levels of AFB1 causing in vivo
acute liver toxicity in rats and humans. Previous work has shown
agreement between predicted QIVIVE data and data from in
vivo studies in experimental animal studies for different toxicity
endpoints.[18,26,59,60] With respect to the liver as target organ,
the acute liver toxicity of the pyrrolizidine alkaloids lasiocarpine
and riddelliine could be predicted based on in vitro toxicity
studies in cryopreserved rat and human hepatocytes and PBK
models for rats and humans to facilitate reverse dosimetry based
QIVIVE.[16,17]
In the present study, cryopreserved pooled Sprague Dawley
rat hepatocytes, cryopreserved pooled human hepatocytes, and
HepaRG cells were used to assess the cytotoxicity of AFB1 in
vitro, while data obtained in similar models and fresh hepato-
cytes, reported in literature, were included for comparison. The
EC50 values obtained for AFB1 cytotoxicity revealed that fresh
hepatocytes of both rats and humans are more sensitive than cry-
opreserved hepatocytes from rats and humans. In rats, the EC50
values obtained with the cryopreserved Sprague Dawley rat hep-
atocytes used in the present study displayed a 60–146-fold higher
EC50 compared with the reported EC50 values obtained with fresh
rat hepatocytes.[54,55] The differences between the different mod-
els might best be ascribed to differences in the activity of the cy-
tochromes P450 (CYP) responsible for bioactivation of AFB1 in
fresh and cryopreserved hepatocytes.[61] In rats, various CYP en-
zymes are reported to be involved in AFB1 metabolism, includ-
ing CYP1A1/2, CYP3A1/2, CYP2C11, and CYP2B1/2,[62] and al-
though the activity of some CYP enzymes, like CYP2A in cryo-
preserved rat hepatocytes can be comparable to that in fresh rat
hepatocytes,[63,64] the activity of other CYP enzymes, like CYP3A,
can be lower.[65]
In humans, CYP1A2, 2B6, 3A4, 3A5, 3A7, and 2A13 are in-
volved in AFB1 phase I metabolism.[42] Although their expres-
sion can largely vary between individuals, CYP3A4 and CYP1A2
are regarded as the main enzymes involved in both detoxification
and biotransformation of AFB1.[36,42] In human, basal expression
of some CYP enzymes is lower in cryopreserved hepatocytes than
in freshly isolated hepatocytes.[66] CYP1A2 is 2–13-fold lower in
cryopreserved hepatocytes, while CYP3A4 is comparable in both,
fresh and cryopreserved, hepatocytes, yet for both CYP enzymes a
large batch-to-batch variation in their expression and inducibility
may occur depending on the donors.[36,66–68] Hence, the observed
differences between fresh and cryopreserved human hepatocytes
observed in the present study may be due to the difference be-
tween fresh and cryopreserved hepatocytes but may also (in part)
be due to the interindividual variability in the expression of CYP
enzymes between the respective donors.
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Figure 5. Predicted in vivo dose–response curves for acute liver toxicity of aflatoxin B1 in A) male rat and B) human obtained by PBKmodeling facilitated
reverse dosimetry of the concentration response curves presented in Figure 2. Dotted lines correspond to fresh hepatocytes. CP = cryopreserved.
Figure 6. Predicted BMDL10-BMDU10 values for acute liver toxicity of AFB1 in male rat obtained by the PBK modeling-facilitated reverse dosimetry
approach using data from fresh hepatocytes by Zhang et al.[54] and Hanigan and Laishes[55] (white rectangle bars). The predicted BMDL10-BMDU10
are compared to POD for ALT or AST response after a single exposure (striped rectangle bars) or repeated exposure (striped gray rectangle bars) and in
vivo male median lethal doses (LD50) (gray rectangle bars). PO = oral, ALT = aminotransferase, and AST = aspartate aminotransferase.
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Figure 7. Predicted BMDL10-BMDU10 values for acute liver toxicity of AFB1 in human obtained by the PBK modeling-facilitated reverse dosimetry
approach using data from fresh human hepatocytes.[54] The predicted BMDL10-BMDU10 (white rectangle bars) are compared to the estimated doses
that can cause a risk of acute aflatoxicosis and possibly fatality in humans[4,9] (gray rectangle bars).
In this study, the developed PBK models describing the kinet-
ics of AFB1 for rats and humans, were shown to result in predic-
tions that were comparable to available in vivo kinetic data for rats
and humans.[15,47] Based on the prediction of Cmax within 1.01–
2.1-fold accuracy, the model was considered suitable for QIVIVE.
In the next step, the in vitro concentration–response curves for
AFB1 cytotoxicity were translated using PBK modeling-based re-
verse dosimetry to dose–response curves, enabling prediction of
PODs for comparison with in vivo data. The predicted BMDL10-
BMDU10 from the rat model were in line with the PODs for liver
toxicity derived from in vivo studies (Figure 6). The LD50 values
derived from data on AFB1 in rats were somewhat higher than
the predicted and observed PODs for liver toxicity like AST and
ALT[48,49,57] which is in line with the expected role of the enzyme
biomarkers as earlier markers of AFB1 induced adverse effects.
Differences observed between the different values predicted and
observed for liver toxicity may be due to differences in the sensi-
tivity of the different rat models with F344 rats being more sen-
sitive than Sprague Dawley rats[46,69] and older rats being more
sensitive than younger ones.[50,53,70]
In humans, the BMDL10 of 77 µg kg−1 bw predicted based on
data from fresh human hepatocytes was in line with the AFB1
dose levels estimated to result in the onset of acute symptoms
and possible fatality by Wild and Gong (20–100 µg kg−1 bw per
day) and by JECFA (20–120 µg kg−1 bw per day).[4,9] It is of inter-
est to note that the current study used pooled liver samples of 13
individuals.[36] This implies that interindividual differences are
not reflected. To account for interindividual variability in AFB1
kinetics, combining the PBK modeling with Monte Carlo analy-
sis as recently done by Ning et al. to predict interindividual varia-
tion in bioactivation and liver toxicity of lasiocarpine[71] could be
considered in a future study.
In conclusion, the PBK modeling-based reverse dosimetry for
QIVIVE used in this study could adequately predict in vivo kinet-
ics. The study also showed a proof-of-principle for QIVIVE by in-
tegrating in vitro data with in silico PBK modeling-based reverse
dosimetry to predict doses that may cause acute liver toxicity of
AFB1 in rats and humans.
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